您当前的位置：

Atuveciclib S-Enantiomer

目录号: PL02964 纯度: ≥99%

Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) 是一种有效的选择性 CDK9 抑制剂，抑制 CDK9/CycT1，IC50 为 16 nM。

CAS No. :250279-81-1

商品编号	规格	价格	会员价
PL02964-5mg	5mg	¥8840.00	请登录
PL02964-10mg	10mg	¥13661.00	请登录
PL02964-50mg	50mg	询价	询价
PL02964-100mg	100mg	询价	询价
PL02964-10mM*1mLinDMSO	10mM*1mLinDMSO	¥9724.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	Atuveciclib S-Enantiomer
英文名称	Atuveciclib S-Enantiomer
Cas No.	250279-81-1
包装储存	Powder -20°C 3 years；4°C 2 years
详情描述	Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) 是一种有效的选择性 CDK9 抑制剂，抑制 CDK9/CycT1，IC50 为 16 nM。

产品详情	Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) 是一种有效的选择性 CDK9 抑制剂，抑制 CDK9/CycT1，IC₅₀ 为 16 nM。
生物活性	Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective CDK9 inhibitor, which inhibits CDK9/CycT1 with an IC 50 of 16 nM.
性状	Solid
IC50 & Target[1][2]	IC50: 16 nM (CDK9/CycT1)
体外研究(In Vitro)	In comparison with Atuveciclib (BAY-1143572), Atuveciclib (BAY-1143572) S-Enantiomer reveals very similar in vitro properties, well within the limits of measurement accuracy; however, with multiple batches of Atuveciclib (BAY-1143572) S-Enantiomer there is a trend toward a slightly lower activity against CDK9 in the biochemical assay (IC50 CDK9/CycT1: 16 nM) and antiproliferative activity against HeLa cells (IC50: 1100 nM) . has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	Atuveciclib (BAY-1143572) S-Enantiomer exhibits blood/plasma ratios of about 1. Relative to Atuveciclib (BAY-1143572), Atuveciclib (BAY-1143572) S-Enantiomer reveals very similar rat PK properties in vivo (CL b : 1.2 L/kg per hour, V ss : 1.2 L/kg, t 1/2 : 0.6 h, F: 53?%). has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Lücking U, et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem. 2017 Nov 8;12(21):1776-1793.

溶解度数据	In Vitro: DMSO : ≥ 113 mg/mL (291.67 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. Lücking U, et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem. 2017 Nov 8;12(21):1776-1793.

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Atuveciclib S-Enantiomer

相关产品

The molarity calculator equation

The dilution calculator equation